Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%

MT Newswires Live

2025/06/03

Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.

Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.

The company's shares jumped 4% in recent trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540741251"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540741251\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540741251?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540741251","market":"sg","top_or_hot":-1,"title":"Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%","media":"MT Newswires Live","content":"<html><body><p> Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.</p><p>Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.</p><p>The company's shares jumped 4% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZelgen Biopharmaceuticals to Present Cancer Drugs at American Oncology Conference; Shares Up 4%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-06-03 13:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.</p><p>Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.</p><p>The company's shares jumped 4% in recent trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688266","symbol_name":"澤璟製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2540741251","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540741251","pubTimestamp":1748928644,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Suzhou Zelgen Biopharmaceuticals  will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.The company's shares jumped 4% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688266":"泽璟制药","BK0239":"医药制造","AFG":"美国金融集团有限公司","BK4107":"财产与意外伤害保险","BK4117":"多元化保险"},"translate_title":"Zelgen Biopharmaceuticals将在美国肿瘤学会议上展示癌症药物；股价上涨4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688266":0.9,"AFG":1},"content_text":"Suzhou Zelgen Biopharmaceuticals (SHA:688266) will present two cancer drugs at the 2025 American Society of Clinical Oncology Annual Meeting after showing positive results during their clinical trials, according to a Tuesday disclosure on the Shanghai bourse.Alveltamig and Nilvanstomig, with the respective codes ZG006 and ZG005, are currently undergoing clinical trials. These drugs have shown safety, efficiency, and high tolerability in patients during the studies, the Chinese drugmaker company said.The company's shares jumped 4% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}